$IMVT (Immunovant, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 8.3%)

Graded daily on value D, growth B-, profitability D-, momentum B. Sector-relative, identical for every user.

Most active credible voices on $IMVT

@semodough (dough) — 13 mentions · 44.4K followers
@stockmktnewz (Evan) — 9 mentions · 1.2M followers
@stevedjacobs (Steve Jacobs) — 6 mentions · 16.8K followers

Recent headlines featuring $IMVT

2026-10-17: S&P 500 slips below the 50-day line as VIX curve turns inverted

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $IMVT are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$IMVT (Immunovant, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 8.3%)

Graded daily on value D, growth B-, profitability D-, momentum B. Sector-relative, identical for every user.

Most active credible voices on $IMVT

@semodough (dough) — 13 mentions · 44.4K followers
@stockmktnewz (Evan) — 9 mentions · 1.2M followers
@stevedjacobs (Steve Jacobs) — 6 mentions · 16.8K followers

Recent headlines featuring $IMVT

2026-10-17: S&P 500 slips below the 50-day line as VIX curve turns inverted

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $IMVT are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$IMVTImmunovant, Inc. · Biotechnology · $5.7B

$27.51

+2.9%

Event thread

Key events, in time order

5 items

2026-09-23CompanyBear
IMVT-1402 PoC study in CLE misses primary endpoint
Company announcement shows study missed statistical significance; market notes indication not key driver
D1 -7.4% · +5d -2.2%
2026-08-10Earnings
Earnings report
D1 -0.2% · +5d +9.6%

3 earlier events

2026-08-06 → 08-07EarningsBull
Stifel Raises PT to $57 on IMVT-1402, Peak Sales Up to ~$5.9B
Stifel cites IMVT-1402 positioning to raise PT and peak sales, reinforcing pipeline value
D1 +1.2% · +5d +5.2%
2 waves of this story
- 2026-08-06 Multiple sources confirm wider Q1 loss with higher R&D spend, yet IMVT-1402 timelines remain on track with cash runway to GD launch.
- 2026-08-07 Stifel cites IMVT-1402 positioning to raise PT and peak sales, reinforcing pipeline value
2026-08-06Earnings
Earnings report
D1 +1.2% · +5d +5.2%
2026-08-068-K filing
8-K: Item 2.02, Item 9.01
D1 +1.2% · +5d +5.2%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

5 items

2026-09-23CompanyBear
IMVT-1402 PoC study in CLE misses primary endpoint
Company announcement shows study missed statistical significance; market notes indication not key driver
D1 -7.4% · +5d -2.2%
2026-08-10Earnings
Earnings report
D1 -0.2% · +5d +9.6%
2026-08-06 → 08-07EarningsBull
Stifel Raises PT to $57 on IMVT-1402, Peak Sales Up to ~$5.9B
Stifel cites IMVT-1402 positioning to raise PT and peak sales, reinforcing pipeline value
D1 +1.2% · +5d +5.2%
2 waves of this story
- 2026-08-06 Multiple sources confirm wider Q1 loss with higher R&D spend, yet IMVT-1402 timelines remain on track with cash runway to GD launch.
- 2026-08-07 Stifel cites IMVT-1402 positioning to raise PT and peak sales, reinforcing pipeline value
2026-08-06Earnings
Earnings report
D1 +1.2% · +5d +5.2%
2026-08-068-K filing
8-K: Item 2.02, Item 9.01
D1 +1.2% · +5d +5.2%

$IMVT (Immunovant, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 8.3%)

Most active credible voices on $IMVT

Recent headlines featuring $IMVT

$IMVT (Immunovant, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 8.3%)

Most active credible voices on $IMVT

Recent headlines featuring $IMVT

IMVT-1402 PoC study in CLE misses primary endpoint

Earnings report

Stifel Raises PT to $57 on IMVT-1402, Peak Sales Up to ~$5.9B

Earnings report

8-K: Item 2.02, Item 9.01

Bull vs bear

Discussion

IMVT-1402 PoC study in CLE misses primary endpoint

Earnings report

Stifel Raises PT to $57 on IMVT-1402, Peak Sales Up to ~$5.9B

Earnings report

8-K: Item 2.02, Item 9.01